CSIMarket
 
Neurometrix Inc   (NASDAQ: NURO)
 
Price: $4.5800 $0.22 5.046%
Day's High: $4.69 Week Perf: 5.53 %
Day's Low: $ 4.33 30 Day Perf: 2.92 %
Volume (M): 35,500 52 Wk High: $ 0.00
Volume (M$): $ 163 52 Wk Avg: $0.00
Open: $4.36 52 Wk Low: $0.00



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 2
 Employees 50
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


NeuroMetrix Inc is a medical device company that focuses on developing and commercializing advanced technologies to aid in the diagnosis and treatment of chronic diseases, particularly those involving the nervous system. The company's flagship product is the Quell device, a wearable neurostimulation device that provides non-invasive pain relief for individuals suffering from chronic pain conditions such as neuropathy, fibromyalgia, and arthritis. In addition to pain management, Neurometrix is also engaged in the development of other medical technologies, including testing platforms and molecular biomarkers, aimed at improving patient care and outcomes. The company is headquartered in Waltham, Massachusetts and operates globally.


   Company Address: 4B Gill Street Woburn 1801 MA
   Company Phone Number: 890-9989   Stock Exchange / Ticker: NASDAQ NURO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BSX   -1.45%    
INSP        2.47% 
MDT   -2.42%    
NVRO      0% 
SYK   -1.22%    
TCMD   -1.63%    
• View Complete Report
   



Merger and Acquisition

NeuroMetrix Set to Join Forces with electroCore: A Strategic Move to Revolutionize Chronic Disease Management

Published Tue, Dec 17 2024 9:05 PM UTC

Breaking News: NeuroMetrix Enters Definitive Merger Agreement with electroCore, Inc.August 13, 2024 — In a significant development in the medical technology sector, NeuroMetrix Inc. (NASDAQ: NURO), a pioneer in wearable therapeutic devices and diagnostic products, has announced a definitive merger agreement with electroCore, Inc. This strategic move is poised to enhance th...

Management Announcement

NeuroMetrix Explores New Horizons: A Deep Dive into the Company's Strategic Alternatives

Published Tue, Aug 13 2024 6:48 PM UTC



In August 2024, NeuroMetrix, Inc., a leading player in the field of medical technology, made a significant announcement that it has initiated a comprehensive review of strategic alternatives. This move took the financial world by storm, with industry experts and investors eagerly speculating on the potential outcomes and the company s future trajectory. NeuroMetrix...

Contract

NeuroMetrix Prioritizes Increased Shareholder Value Following Strategic Steps and Valuable Shareholder Feedback.

Published Fri, Apr 19 2024 12:00 PM UTC

NeuroMetrix, a pioneering health-care firm focusing on developing and marketing cutting-edge wearable medical technology, today announced significant strides taken to increase shareholder value. This recent came into action following valuable feedback and advice from one of its most significant shareholders. The aim was to create and establish better and stronger financial ...

Clinical Study

Novel Study Confirms the Accuracy of DPNCheck in Diagnosing Diabetic Peripheral Neuropathy

Published Thu, Mar 14 2024 1:00 PM UTC

presents remarkable findings from a recent publication by NeuroMetrix, Inc., announcing the successful detection of diabetic peripheral neuropathy (DPN) using DPNCheck technology. The study highlights the effectiveness of DPNCheck as a standalone method or in combination with standard electrocardiography (EKG) for accurately diagnosing DPN.Study Overview:In a groundbreaking...

Product Service News

NeuroMetrix's Strategic Review Sets Path for Neurological Innovation and Growth

Published Tue, Feb 13 2024 2:00 PM UTC

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueWOBURN, Mass., Feb. 13, 2024 - NeuroMetrix, Inc. (Nasdaq: NURO), a leading medical device company specializing in reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, has recently announced the initiation of a strategi...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.37
Price to Sales (Expected) -
Price to Book 0.63
PEG (TTM) -

Financial Strength Current
Quick Ratio 14.47
Working Capital Ratio 16.59
Leverage Ratio (MRQ) 0.06
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.06 $
Revenues (TTM) 1.36 $
Cash Flow (TTM) -
Cash 6.65 $
Book Value 7.27 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 53,593
Net Income per Employee (TTM) -156,121
Receivable Turnover Ratio (TTM) 9.81
Inventory Turnover Ratio (TTM) 0.95
Asset Turnover Ratio (TTM) 0.15

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -852.32 %
Net Margin (MRQ) -775.24 %
Net Cash Flow Margin (MRQ) 220.45 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.